- Home
- QNRX vs CNSP Comparison
QNRX vs CNSP Comparison
Compare QNRX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- CNSP
- Stock Information
- Founded
- QNRX 2018
- CNSP 2017
- Country
- QNRX United States
- CNSP United States
- Employees
- QNRX N/A
- CNSP N/A
- Industry
- QNRX Medical/Dental Instruments
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- CNSP Health Care
- Exchange
- QNRX Nasdaq
- CNSP Nasdaq
- Market Cap
- QNRX 4.3M
- CNSP 4.0M
- IPO Year
- QNRX N/A
- CNSP 2019
- Fundamental
- Price
- QNRX $7.20
- CNSP $6.48
- Analyst Decision
- QNRX
- CNSP Hold
- Analyst Count
- QNRX 0
- CNSP 1
- Target Price
- QNRX N/A
- CNSP N/A
- AVG Volume (30 Days)
- QNRX 4.5K
- CNSP 80.0K
- Earning Date
- QNRX 08-07-2025
- CNSP 08-14-2025
- Dividend Yield
- QNRX N/A
- CNSP N/A
- EPS Growth
- QNRX N/A
- CNSP N/A
- EPS
- QNRX N/A
- CNSP N/A
- Revenue
- QNRX N/A
- CNSP N/A
- Revenue This Year
- QNRX N/A
- CNSP N/A
- Revenue Next Year
- QNRX N/A
- CNSP N/A
- P/E Ratio
- QNRX N/A
- CNSP N/A
- Revenue Growth
- QNRX N/A
- CNSP N/A
- 52 Week Low
- QNRX $5.01
- CNSP $4.93
- 52 Week High
- QNRX $54.95
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- QNRX 43.44
- CNSP 43.40
- Support Level
- QNRX $7.05
- CNSP $4.93
- Resistance Level
- QNRX $7.30
- CNSP $7.32
- Average True Range (ATR)
- QNRX 0.33
- CNSP 0.93
- MACD
- QNRX 0.05
- CNSP 0.09
- Stochastic Oscillator
- QNRX 41.14
- CNSP 55.06
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.